Sweden's Bactiguard Q1 revenue falls 25% on currency impact

Bactiguard Holding AB

23/04/2026 06:17

Overview

Sweden MedTech firm's Q1 revenue fell 25% yr/yr amid negative currency effects and timing issues

Adjusted EBITDA remained positive despite lower revenue, reflecting continued profitability

Company invested in regulatory activities and strengthened leadership team to support growth

Outlook

Company says quarterly revenues will vary due to currency, regulatory timing, and license agreements

Bactiguard to continue strengthening partnerships, advancing regulatory pathways, and driving growth in Wound Management

Company sees infection prevention as a growing global healthcare priority supporting long-term demand

Result Drivers

CURRENCY EFFECTS - Co said negative currency effects reduced reported net sales by SEK 5.9 mln and affected profitability

LICENSE REVENUE TIMING - Lower license revenues reflected timing in the license business and a strong comparison quarter last year, per CEO

WOUND MANAGEMENT - Wound Management portfolio generated SEK 18.2 mln in revenue, lower than last year but still seen as solid performance, with Hydrocyn aqua as main contributor

Company press release: ID:nMFN8SYLrr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 46.90 mln
SEK 51 mln (1 Analyst)
Q1 Adjusted EPS
-SEK 0.16
Q1 Net Income
-SEK 5.60 mln
Q1 EBITDA
SEK 4.10 mln
Q1 Operating Cash Flow
-SEK 7.40 mln
Q1 Operating Profit
-SEK 7.20 mln


Analyst Coverage

Wall Street's median 12-month price target for Bactiguard Holding AB is SEK22.50, about 28.2% above its April 22 closing price of SEK17.55

The stock recently traded at 302 times the next 12-month earnings vs. a P/E of 226 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)